Working... Menu
Trial record 75 of 2838 for:    Pancreatic Cancer

Safety and Efficiency of γδ T Cell Against Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03180437
Recruitment Status : Recruiting
First Posted : June 8, 2017
Last Update Posted : June 8, 2017
Jinan University Guangzhou
Information provided by (Responsible Party):
Fuda Cancer Hospital, Guangzhou

Brief Summary:
In this study, effects of γδT cells on human Pancreatic Cancer in combination with tumor reducing surgery, for example cryosurgery going to be investigated.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Procedure: Cryosurgery or IRE surgery Biological: γδ T cell Other: γδ T cells/ A Cryosurgery or IRE Phase 1 Phase 2

Detailed Description:

Pancreatic tumor will be removed using tumor reducing surgery such as cryosurgery.

PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as an immunotherapy treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: γδ T Cell Immunotherapy for Treatment of Pancreatic Cancer
Estimated Study Start Date : June 15, 2017
Estimated Primary Completion Date : June 15, 2018
Estimated Study Completion Date : June 15, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Group A
In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor.
Procedure: Cryosurgery or IRE surgery
Cryosurgery or IRE surgery will be used in local tumor

Experimental: Group B
In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
Biological: γδ T cell
γδ T cells will be used against Pancreatic Cancer

Experimental: Group C
In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
Other: γδ T cells/ A Cryosurgery or IRE
Combination γδ T cell and Cryosurgery or IRE surgery will be used in Pancreatic Cancer

Primary Outcome Measures :
  1. Relief degree of tumors [ Time Frame: 3 months ]
    It will be evaluated by the Response Evaluation Criteria in Solid Tumors(RECIST)

  2. Progress free survival(PFS) [ Time Frame: 1 year ]
  3. Overall survival(OS) [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age: 18-75
  2. Karnofsky performance status >50
  3. Diagnosis with Pancreatic Cancer based on histology or the current accepted radiological measures
  4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ
  5. Will receive cryosurgery, IRE, gd Tcells
  6. Life expectancy: Greater than 3 months
  7. Ability to understand the study protocol and a willingness to sign a written informed consent document

Exclusion Criteria:

  1. Patients with other kinds of cancer
  2. History of coagulation disorders or anemia
  3. Patients with heart disease and diabetes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03180437

Layout table for location contacts
Contact: Mohammed Alnaggar, Post Doc 008613826185510

Layout table for location information
China, Guangdong
Biotherapy center in Fuda cancer hospital Recruiting
Guangzhou, Guangdong, China, 510665
Contact: Moahmmed Alnaggar, M.D    +86-13826185510   
Sponsors and Collaborators
Fuda Cancer Hospital, Guangzhou
Jinan University Guangzhou
Layout table for investigator information
Principal Investigator: Jibing Chen, PhD Biological treatment center in Fuda cancer hospital Guangzhou, Guangdong, China, 510000

Layout table for additonal information
Responsible Party: Fuda Cancer Hospital, Guangzhou Identifier: NCT03180437     History of Changes
Other Study ID Numbers: Gd T cell and Pancreatic Ca
First Posted: June 8, 2017    Key Record Dates
Last Update Posted: June 8, 2017
Last Verified: June 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Fuda Cancer Hospital, Guangzhou:
γδ T Cell
Pancreatic Cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Immunologic Factors
Physiological Effects of Drugs